Tyr323-dependent p38 activation is associated with rheumatoid arthritis and correlates with disease activity

Dong, 2002, MAP kinases in the immune response, Annu Rev Immunol, 20, 55, 10.1146/annurev.immunol.20.091301.131133

Chang, 2001, Mammalian MAP kinase signalling cascades, Nature, 410, 37, 10.1038/35065000

Kato, 1997, BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C, EMBO J, 16, 7054, 10.1093/emboj/16.23.7054

Davis, 2000, Signal transduction by the JNK group of MAP kinases, Cell, 103, 239, 10.1016/S0092-8674(00)00116-1

Ambrosino, 2001, Cell cycle regulation by p38 MAP kinases, Biol Cell, 93, 47, 10.1016/S0248-4900(01)01124-8

Crawley, 1997, T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation, J Biol Chem, 272, 15023, 10.1074/jbc.272.23.15023

Rincon, 1998, Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway, EMBO J, 17, 2817, 10.1093/emboj/17.10.2817

Merritt, 2000, Activation of p38 mitogen-activated protein kinase in vivo selectively induces apoptosis of CD8+ but not CD4+ T cells, Mol Cell Biol, 20, 936, 10.1128/MCB.20.3.936-946.2000

Rincon, 2003, JNK and p38 MAP kinases in CD4+ and CD8+ T cells, Immunol Rev, 192, 131, 10.1034/j.1600-065X.2003.00019.x

Miossec, 1997, Th1/Th2 cytokine balance in arthritis, Arthritis Rheum, 40, 2105, 10.1002/art.1780401203

Miossec, 1997, The role of the Th1 and Th2 dichotomy in the pathogenesis of juvenile chronic arthritis, Rev Rhum Engl Ed, 64, 138

Han, 1994, A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells, Science, 265, 808, 10.1126/science.7914033

Rouse, 1994, A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins, Cell, 78, 1027, 10.1016/0092-8674(94)90277-1

Lee, 1994, A protein kinase involved in the regulation of inflammatory cytokine biosynthesis, Nature, 372, 739, 10.1038/372739a0

Freshney, 1994, Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27, Cell, 78, 1039, 10.1016/0092-8674(94)90278-X

Kumar, 2003, p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases, Nat Rev Drug Discov, 2, 717, 10.1038/nrd1177

Badger, 1996, Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function, J Pharmacol Exp Ther, 279, 1453

Badger, 2000, Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis, Arthritis Rheum, 43, 175, 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S

Pargellis, 2003, Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis, Curr Opin Investig Drugs, 4, 566

Wada, 2005, R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models, Eur J Pharmacol, 506, 285, 10.1016/j.ejphar.2004.11.013

Thalhamer, 2008, MAPKs and their relevance to arthritis and inflammation, Rheumatology (Oxford), 47, 409, 10.1093/rheumatology/kem297

Derijard, 1995, Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms, Science, 267, 682, 10.1126/science.7839144

Raingeaud, 1996, MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway, Mol Cell Biol, 16, 1247, 10.1128/MCB.16.3.1247

Jiang, 1997, Structure-function studies of p38 mitogen-activated protein kinase: loop 12 influences substrate specificity and autophosphorylation, but not upstream kinase selection, J Biol Chem, 272, 11096, 10.1074/jbc.272.17.11096

Bellon, 1999, The structure of phosphorylated p38γ is monomeric and reveals a conserved activation-loop conformation, Structure, 7, 1057, 10.1016/S0969-2126(99)80173-7

Salvador, 2005, Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases, Nat Immunol, 6, 390, 10.1038/ni1177

Mittelstadt, 2005, Activating p38 MAPK: new tricks for an old kinase, Cell Cycle, 4, 1189, 10.4161/cc.4.9.2043

Rudd, 2005, MAPK p38: alternative and nonstressful in T cells, Nat Immunol, 6, 368, 10.1038/ni0405-368

Ashwell, 2006, The many paths to p38 mitogen-activated protein kinase activation in the immune system, Nat Rev Immunol, 6, 532, 10.1038/nri1865

Salvador, 2005, The autoimmune suppressor Gadd45α inhibits the T cell alternative p38 activation pathway, Nat Immunol, 6, 396, 10.1038/ni1176

Jirmanova, 2009, Genetic disruption of p38α Tyr323 phosphorylation prevents T-cell receptor-mediated p38α activation and impairs interferon-γ production, Blood, 113, 2229, 10.1182/blood-2008-04-153304

Arnett, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, 31, 315, 10.1002/art.1780310302

Van der Linden, 1984, Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria, Arthritis Rheum, 27, 361, 10.1002/art.1780270401

Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, 38, 44, 10.1002/art.1780380107

Salvador, 2002, Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome, Immunity, 16, 499, 10.1016/S1074-7613(02)00302-3

Hardin, 2007, Generalized linear models and extensions

Garfield, 2005, Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis, Clin Immunol, 116, 101, 10.1016/j.clim.2005.04.010

Liu, 2007, T cell-directed therapies: lessons learned and future prospects, Nat Immunol, 8, 25, 10.1038/ni1429

Isaacs, 2008, Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future, Rheumatology (Oxford), 47, 1461, 10.1093/rheumatology/ken163

Cope, 2008, T cells in rheumatoid arthritis, Arthritis Res Ther, 10, S1, 10.1186/ar2412

Ge, 2002, MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α, Science, 295, 1291, 10.1126/science.1067289

Ohkusu-Tsukada, 2004, Regulation of the maintenance of peripheral T-cell anergy by TAB1-mediated p38α activation, Mol Cell Biol, 24, 6957, 10.1128/MCB.24.16.6957-6966.2004

Kim, 2005, p38 MAPK autophosphorylation drives macrophage IL-12 production during intracellular infection, J Immunol, 174, 4178, 10.4049/jimmunol.174.7.4178

Zhou, 2006, Determinants that control the specific interactions between TAB1 and p38α, Mol Cell Biol, 26, 3824, 10.1128/MCB.26.10.3824-3834.2006

Diskin, 2007, Structures of p38α active mutants reveal conformational changes in L16 loop that induce autophosphorylation and activation, J Mol Biol, 365, 66, 10.1016/j.jmb.2006.08.043

Mittelstadt, 2009, T cell receptor-mediated activation of p38α by mono-phosphorylation of the activation loop results in altered substrate specificity, J Biol Chem, 284, 15469, 10.1074/jbc.M901004200

Round, 2007, Scaffold protein Dlgh1 coordinates alternative p38 kinase activation, directing T cell receptor signals toward NFAT but not NF-κB transcription factors, Nat Immunol, 8, 154, 10.1038/ni1422